172 related articles for article (PubMed ID: 16750861)
1. Functional characterization of OX40 expressed on human CD8+ T cells.
Fujita T; Ukyo N; Hori T; Uchiyama T
Immunol Lett; 2006 Jul; 106(1):27-33. PubMed ID: 16750861
[TBL] [Abstract][Full Text] [Related]
2. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
3. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Mendel I; Shevach EM
Immunology; 2006 Feb; 117(2):196-204. PubMed ID: 16423055
[TBL] [Abstract][Full Text] [Related]
4. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
5. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.
al-Shamkhani A; Birkeland ML; Puklavec M; Brown MH; James W; Barclay AN
Eur J Immunol; 1996 Aug; 26(8):1695-9. PubMed ID: 8765008
[TBL] [Abstract][Full Text] [Related]
6. Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions.
Kondo K; Okuma K; Tanaka R; Matsuzaki G; Ansari AA; Tanaka Y
Hum Immunol; 2008 Sep; 69(9):533-42. PubMed ID: 18718855
[TBL] [Abstract][Full Text] [Related]
7. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
8. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
Ahn JS; Krishnadas DK; Agrawal B
Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
[TBL] [Abstract][Full Text] [Related]
10. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of IL-17 production by OX40/OX40L interaction.
Li J; Li L; Shang X; Benson J; Merle Elloso M; Schantz A; Bracht M; Orlovsky Y; Sweet R
Cell Immunol; 2008; 253(1-2):31-7. PubMed ID: 18501882
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.
Mestas J; Crampton SP; Hori T; Hughes CC
Int Immunol; 2005 Jun; 17(6):737-47. PubMed ID: 15908450
[TBL] [Abstract][Full Text] [Related]
13. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
14. Activated CD4+ CD25+ T cells suppress antigen-specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells.
Dieckmann D; Plöttner H; Dotterweich S; Schuler G
Immunology; 2005 Jul; 115(3):305-14. PubMed ID: 15946248
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system.
Kunitomi A; Hori T; Imura A; Uchiyama T
J Leukoc Biol; 2000 Jul; 68(1):111-8. PubMed ID: 10914497
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
Tenorio EP; Saavedra R
Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
[TBL] [Abstract][Full Text] [Related]
17. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
18. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
19. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
20. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
